Delivered
Michigan
Destination state
Carrier-confirmed deliveryThe supplied tracking record shows this shipment as delivered.
Recipient details withheld
Medical Review Statement
Educational content updated October 1, 2026 using the sources listed below. Medically reviewed by Dr. Fremlin Dekyi, MD. Reviewed: October 1, 2026. This content does not replace individualized medical advice.
Quick Answer
Semaglutide is an ingredient; Wegovy and Ozempic are brands
Wegovy and Ozempic both contain semaglutide. They are not three different active ingredients, and their approved indications and dosing are not interchangeable. A prescription labeled only 'semaglutide' should be clarified with the prescriber and pharmacy.
Ingredient and brand comparison
| Question | Semaglutide | Wegovy | Ozempic |
|---|---|---|---|
| What is it? | Active ingredient, not one specific product | Semaglutide brand for weight management and other labeled uses | Semaglutide injection brand for type 2 diabetes |
| FDA approval | Approval attaches to a specific finished product; compounded semaglutide is not FDA-approved | Weight management; cardiovascular risk reduction in eligible adults; injection also has an accelerated-approval MASH indication | Type 2 diabetes glucose control; cardiovascular risk reduction in eligible adults; kidney/CV risk reduction in adults with type 2 diabetes and chronic kidney disease |
| Who is it intended for? | Depends on the prescribed product | Adults with obesity or overweight plus a weight-related condition; injection also for adolescents 12+ with obesity | Adults with type 2 diabetes; use for weight loss alone is off-label |
| Form / dosing | Depends on brand and formulation | Weekly injection begins at 0.25 mg; usual maintenance 2.4 mg. Label also includes 7.2 mg HD for eligible adults and daily tablets with 25 mg maintenance | Weekly injection begins at 0.25 mg for 4 weeks, then 0.5 mg; may rise to 1 or 2 mg after at least 4 weeks at the preceding dose |
| Cost / insurance | Product, pharmacy and indication determine the bill | Weight-management benefits and prior authorization often determine coverage | Diabetes diagnosis and plan requirements often determine coverage |
Why brands, forms and doses matter
The same ingredient does not make pens or tablets interchangeable. Oral milligrams are not equivalent to injected milligrams. Do not copy a dose from another product, combine semaglutide products or substitute a compounded preparation without prescriber review.
Ask which exact product you are being prescribed, whether its use is on-label or off-label, what evidence supports it, how it is supplied and the total cost. Doko's program pricing should not be treated as a quotation for every branded medicine.
How a clinician chooses between treatments
A clinician weighs your treatment goal, diabetes status, cardiovascular history, sleep apnea, kidney health, gastrointestinal tolerance, other medicines, pregnancy plans and access. A trial average cannot predict your individual response. Do not combine these medicines or switch doses yourself.
Ask your insurer about the exact brand and indication: formulary status, prior authorization, documented BMI and conditions, step therapy and renewal requirements can differ. Compare the total ongoing cost, including visits, labs, pharmacy charges and supplies; introductory prices and savings offers may change.
What to discuss with your clinician
- Your diagnosis, treatment goals and medical history.
- The exact product, dose, safety precautions and ongoing cost.
- Your follow-up plan and symptoms that need prompt assessment.
Best next step
Use consultation to turn search intent into a real treatment decision
Patients usually get more value from medical review, fit assessment, and follow-up planning than from choosing a medication based only on headlines or social posts.
Frequently asked questions
Ozempic is not FDA-approved for chronic weight management. Wegovy is the semaglutide brand with that indication; a clinician may discuss off-label treatment where appropriate.
No. Compounded preparations are not FDA-approved generics and are not reviewed by FDA for safety, effectiveness or quality before marketing.
No. Coverage can differ by brand and indication. Check your plan's diabetes and obesity benefits and prior authorization requirements.
